Repligen (NASDAQ:RGEN) Price Target Lowered to $150.00 at HSBC

Repligen (NASDAQ:RGEN) had its price target reduced by HSBC from $170.00 to $150.00 in a report issued on Wednesday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other research firms also recently weighed in on RGEN. Barclays lifted their price target on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. UBS Group lowered their price objective on shares of Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. Wall Street Zen downgraded shares of Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. KeyCorp restated an “overweight” rating on shares of Repligen in a research report on Wednesday, February 25th. Finally, Roth Mkm began coverage on shares of Repligen in a research report on Friday, April 17th. They set a “buy” rating and a $160.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Repligen presently has an average rating of “Moderate Buy” and an average price target of $164.64.

Repligen Stock Up 0.5%

NASDAQ RGEN opened at $121.73 on Wednesday. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. Repligen has a 1-year low of $100.99 and a 1-year high of $175.77. The company has a 50 day moving average of $118.30 and a 200-day moving average of $139.07. The company has a market cap of $6.87 billion, a price-to-earnings ratio of 135.26, a PEG ratio of 2.33 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company had revenue of $194.26 million during the quarter, compared to the consensus estimate of $192.05 million. During the same period in the previous year, the business earned $0.39 earnings per share. The firm’s quarterly revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, equities research analysts expect that Repligen will post 1.99 earnings per share for the current fiscal year.

Institutional Trading of Repligen

Institutional investors have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC boosted its position in Repligen by 1.9% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 4,001 shares of the biotechnology company’s stock valued at $584,000 after acquiring an additional 75 shares during the last quarter. NewEdge Wealth LLC boosted its position in Repligen by 5.3% during the fourth quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock valued at $244,000 after acquiring an additional 75 shares during the last quarter. UMB Bank n.a. boosted its position in Repligen by 13.8% during the fourth quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 92 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its position in Repligen by 0.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock valued at $4,542,000 after acquiring an additional 100 shares during the last quarter. Finally, Coldstream Capital Management Inc. boosted its position in Repligen by 5.3% during the fourth quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock valued at $326,000 after acquiring an additional 101 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.